more_reports

The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports

Canadian Biotech Advances High-Impact DDR Programs

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) secures CA$4M in strategic funding, boosts AI-powered cancer programs, and eyes 300% potential return with DDR breakthroughs. Read more about the companys scientific momentum, analyst coverage, and AI-driven oncology strategy.
Tags: Biotechnology / Pharmaceuticals

Biotech Company Unlocks Gene Therapy Breakthrough in Canada

  ()
PreveCeutical Preventive Health Sciences (PREV:CSE; PRVCF:OTC; 18H:FSE) moves gene and pain therapy assets into new entities in Canada, with proof-of-concept studies signaling major delivery breakthroughs. Find out how the company's strategy to form independent entities and leverage proprietary delivery platforms is positioning it for growth across multiple therapeutic markets.
Tags: Biotechnology / Pharmaceuticals

Data Readout Positive from Trial of New Schizophrenia Drug

Research Report
  ()
This new dopamine-serotonin system modulator showed sustained efficacy over 52 weeks and a favorable tolerability and safety profile, noted a D. Boral Capital report.
Tags: Biotechnology / Pharmaceuticals

Biotech Firm Gains Exclusive Alzheimer's Rights in U.S. and Canada

  ()
Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) secures exclusive Alzheimer's clinic rights in Canada and key U.S. cities, positioning for a high-growth breakthrough. Learn how Algernon plans to launch cutting-edge clinics featuring PET scan technology and expand into a multibillion-dollar diagnostics market
Tags: Biotechnology / Pharmaceuticals

A Health Sciences Stock Positioned To Break Out of a Giant Base Pattern

Contributed Opinion
  ()
Technical Analyst Clive Maund explains why he thinks PreveCeutical Medical Inc. (PREV:CSE; PRVCF:OTCMKTS) is ready to break out and is rated a Strong Buy.
Tags: Biotechnology / Pharmaceuticals

Co. Poised to Begin Major New Bull Market

Contributed Opinion
  ()
Technical Analyst Clive Maund explains why he thinks Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) is an Immediate Strong Buy.
Tags: TechnologySpecial SituationsLife Sciences Tools & DiagnosticsBiotechnology / Pharmaceuticals

Co. Prepares to Roll Out Wound Irrigating Solution

Research Report
  ()
BioLargo Inc.'s (BLGO:OTCQX) subsidiary has all the necessary partners in place and working on integrating the various systems, such as purchasing, accounting, forecasting, logistics and quality assurance, noted an Oak Ridge Financial report.
Tags: Biotechnology / Pharmaceuticals

Biotech Firm Unlocks Alzheimer's Market with U.S. Clinic Launch

  ()
Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) has acquired NoBrainer Imaging, unlocking Alzheimer's PET scan clinics in Florida, Los Angeles, five select U.S. cities, and Canada. Read more to explore the growth potential.
Tags: Biotechnology / Pharmaceuticals

Biopharma Receives PDUFA Date for Lead Program

Research Report
  ()
This is a critical milestone for the company and significant for the space given the lack of approved therapies, noted a D. Boral Capital report.
Tags: Biotechnology / Pharmaceuticals

Biopharma Shares Efficacy Data at AUA Meeting

Research Report
  ()
These results and input from key opinion leaders boost "our enthusiasm for this candidate's prospects as a treatment for non-muscle, invasive bladder cancer, noted an Oppenheimer report.
Tags: Biotechnology / Pharmaceuticals

New Cell Treatment for Bladder Cancer Shows Promise

Research Report
  ()
This investigative therapy is "uniquely positioned to occupy a distinct segment" within the evolving and crowded space, noted an H.C. Wainwright & Co. report.
Tags: Biotechnology / Pharmaceuticals

Biotech Co. Achieves Remarkable Cancer Treatment Results in Trial

  ()
Clinical-stage biopharmaceutical company Protara Therapeutics Inc. (TARA:NASDAQ) announces updated results from its trials of a drug for high-risk non-muscle invasive bladder cancer (NMIBC). Read why analysts are recommending this biopharmaceutical stock.
Tags: Biotechnology / Pharmaceuticals

Biotech Firm Uncovers Long-Term Cancer Breakthrough in Nevada

  ()
UroGen Pharma Ltd. (URGN:NASDAQ) unveiled nearly four years of durable response for JELMYTO in Nevada, offering a breakthrough for low-grade upper tract cancer patients. See how UroGen Pharmas breakthrough data could reshape non-surgical cancer treatments and drive future growth in the oncology sector.
Tags: Biotechnology / Pharmaceuticals

Biotech Company Reports Promising Neurological Treatment in Clinical Study

  ()
Clinical-stage biotechnology company Coya Therapeutics Inc. (COYA:NASDAQ) announces positive interim results of a study for the treatment of patients with frontotemporal dementia (FTD). Read to see what catalysts one analyst said the stock can look forward to this year.
Tags: Biotechnology / Pharmaceuticals

Biotech Discovers Revolutionary Immunotherapy in Houston

Research Report
  ()
Coya Therapeutics Inc. (COYA:NASDAQ) recently reported a statistically significant Treg improvement in FTD patients with its dual-action immunotherapy, showing promising neuroprotection, according to a D. Boral research note.
Tags: Biotechnology / Pharmaceuticals

Biopharma Company Leverages AI-Powered Platform for Cancer Breakthroughs

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) announced its scientific advisor and collaborator Dr. Artem Cherkasov was recently recognized as a leader in AI-driven drug development. Find out which analysts recently initiated coverage on the company.
Tags: Biotechnology / PharmaceuticalsLife Sciences Tools & Diagnostics

Analyst Reveals Undervalued Pharmaceutical Gem in Canada

Research Report
  ()
In a recent research note from Leede Financial Inc. analyst Dr. Douglas Loe said Theratechnologies Inc. (TH:TSX; THTX:NASDAQ) has long term potential.
Tags: Biotechnology / Pharmaceuticals

New Drug for Early AD Shown to be Efficacious, Safe

Research Report
  ()
Trial participants exhibited improvements in cognitive function and activities of daily living, noted a D. Boral Capital report.
Tags: Biotechnology / Pharmaceuticals

Rest of 2025 Rich With Catalysts for Immunotherapy Co.

Research Report
  ()
These anticipated events will advance the oncology firm's lead candidate, for lung-only metastatic osteosarcoma, toward commercialization, noted a D. Boral Capital report.
Tags: Biotechnology / Pharmaceuticals

Four-Year Data on New Drug for Early AD Positive

Research Report
  ()
Long-term treatment with this small molecule seems feasible given its safety and tolerability profile, noted an H.C. Wainwright & Co. report.
Tags: Biotechnology / Pharmaceuticals

Share Price Appreciation of Biotech Due Over Next Six Months

Research Report
  ()
Given its robust pipeline, numerous milestones for this Outperform-rated company are slated to occur in the near-term, noted a Wedbush report.
Tags: Biotechnology / Pharmaceuticals

New Therapy for AATD Could be Best in Class

Research Report
  ()
Updated trial data show it to be safe and efficacious and have a dual mechanism of action, noted an H.C. Wainwright & Co. report.
Tags: Biotechnology / Pharmaceuticals

Biotech Firm Uncovers Gene Therapy Breakthrough in Portugal

  ()
Beam Therapeutics Inc. (BEAM:NASDAQ) shows strong momentum with positive analyst ratings and new data from its BEAM-302 trial in AATD. Find out why experts see major upside potential.
Tags: Biotechnology / Pharmaceuticals

Biotech Co. Has Promising AI-Accelerated Pipeline

Research Report
  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) recently gained analyst coverage from First Berlin Equity Research. Read on to see why this company rates the stock a Buy.
Tags: Biotechnology / Pharmaceuticals

Immunotherapy Company Finds Rare Cancer Breakthrough in U.S.

  ()
OS Therapies Inc. (OSTX:NYSEAMERICAN) announced that its lead drug OST-HER2 was granted Orphan Drug Designation by the FDA for osteosarcoma. Read how the designation could accelerate development and create new investor interest.
Tags: Biotechnology / Pharmaceuticals

Showing Results: 1 to 25 of 68 Next